Notice to Stakeholders – Clarification of Requirements under the Food and Drug Regulations and the Controlled Drugs and Substances Act When Conducting Clinical Research with Psilocybin (English, HTML)
Notice to Stakeholders – Clarification of Requirements under the Food and Drug Regulations and the Controlled Drugs and Substances Act When Conducting Clinical Research with Psilocybin: English HTML file. From Health Canada, updated Oct 2023. View metadata, licence and the direct download on CanQuery.
- Format
- HTML
- Access
- Original download only
- Publisher-reported update
- 2023-10-29
Health Canada is issuing this notice to clinical trial sponsors to clarify the approach to clinical research with psilocybin. Health Canada recognizes that conducting clinical research (i.e., research carried out on humans) is a critical step in the generation of good quality evidence needed to better understand the potential health benefits and harms associated with the therapeutic use of psilocybin.
Data overview
- Formats
- HTML
- File languages
- English
- Available actions
- Access original file